107 related articles for article (PubMed ID: 9865497)
1. Effects of IFN alpha on late stages of HIV-1 replication cycle.
Dianzani F; Castilletti C; Gentile M; Gelderblom HR; Frezza F; Capobianchi MR
Biochimie; 1998; 80(8-9):745-54. PubMed ID: 9865497
[TBL] [Abstract][Full Text] [Related]
2. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.
Hansen BD; Nara PL; Maheshwari RK; Sidhu GS; Bernbaum JG; Hoekzema D; Meltzer MS; Gendelman HE
J Virol; 1992 Dec; 66(12):7543-8. PubMed ID: 1279206
[TBL] [Abstract][Full Text] [Related]
3. Interferon treatment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins.
Agy MB; Acker RL; Sherbert CH; Katze MG
Virology; 1995 Dec; 214(2):379-86. PubMed ID: 8553538
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.
Smith MS; Thresher RJ; Pagano JS
Antimicrob Agents Chemother; 1991 Jan; 35(1):62-7. PubMed ID: 1707604
[TBL] [Abstract][Full Text] [Related]
5. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
[TBL] [Abstract][Full Text] [Related]
6. 90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1.
Lodermeyer V; Suhr K; Schrott N; Kolbe C; Stürzel CM; Krnavek D; Münch J; Dietz C; Waldmann T; Kirchhoff F; Goffinet C
Retrovirology; 2013 Oct; 10():111. PubMed ID: 24156545
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
Bryant ML; Ratner L; Duronio RJ; Kishore NS; Devadas B; Adams SP; Gordon JI
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2055-9. PubMed ID: 2006142
[TBL] [Abstract][Full Text] [Related]
8. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
9. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.
Davis MR; Jiang J; Zhou J; Freed EO; Aiken C
J Virol; 2006 Mar; 80(5):2405-17. PubMed ID: 16474147
[TBL] [Abstract][Full Text] [Related]
10. Induction of IFN-alpha by HIV-1 in monocyte-enriched PBMC requires gp120-CD4 interaction but not virus replication.
Francis ML; Meltzer MS
J Immunol; 1993 Aug; 151(4):2208-16. PubMed ID: 8345204
[TBL] [Abstract][Full Text] [Related]
11. Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein.
Babé LM; Unal A; Craik CS
J Interferon Cytokine Res; 1997 May; 17(5):287-93. PubMed ID: 9181467
[TBL] [Abstract][Full Text] [Related]
12. Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.
Misra A; Gleeson E; Wang W; Ye C; Zhou P; Kimata JT
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321330
[TBL] [Abstract][Full Text] [Related]
13. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.
Schätzl H; Gelderblom HR; Nitschko H; von der Helm K
Arch Virol; 1991; 120(1-2):71-81. PubMed ID: 1929879
[TBL] [Abstract][Full Text] [Related]
14. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation.
Navarro J; Punzón MC; Pizarro A; Fernández-Cruz E; Fresno M; Muñoz-Fernández MA
AIDS; 1996 May; 10(5):469-75. PubMed ID: 8724037
[TBL] [Abstract][Full Text] [Related]
16. Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells.
Wachinger M; Saermark T; Erfle V
FEBS Lett; 1992 Sep; 309(3):235-41. PubMed ID: 1516693
[TBL] [Abstract][Full Text] [Related]
17. The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific.
Lodermeyer V; Ssebyatika G; Passos V; Ponnurangam A; Malassa A; Ewald E; Stürzel CM; Kirchhoff F; Rotger M; Falk CS; Telenti A; Krey T; Goffinet C
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743357
[TBL] [Abstract][Full Text] [Related]
18. Annexin 2: a novel human immunodeficiency virus type 1 Gag binding protein involved in replication in monocyte-derived macrophages.
Ryzhova EV; Vos RM; Albright AV; Harrist AV; Harvey T; González-Scarano F
J Virol; 2006 Mar; 80(6):2694-704. PubMed ID: 16501079
[TBL] [Abstract][Full Text] [Related]
19. Human Polycomb group EED protein negatively affects HIV-1 assembly and release.
Rakotobe D; Tardy JC; André P; Hong SS; Darlix JL; Boulanger P
Retrovirology; 2007 Jun; 4():37. PubMed ID: 17547741
[TBL] [Abstract][Full Text] [Related]
20. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.
Hammonds J; Chen X; Ding L; Fouts T; De Vico A; zur Megede J; Barnett S; Spearman P
Virology; 2003 Sep; 314(2):636-49. PubMed ID: 14554091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
